Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

86.61EUR
28 Apr 2017
Change (% chg)

€0.64 (+0.74%)
Prev Close
€85.97
Open
€87.00
Day's High
€88.00
Day's Low
€86.17
Volume
3,454,507
Avg. Vol
2,386,622
52-wk High
€88.00
52-wk Low
€62.50

Latest Key Developments (Source: Significant Developments)

Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA
Friday, 28 Apr 2017 01:00am EDT 

April 28 (Reuters) - Sanofi :Regeneron and Sanofi announce Kevzara® (sarilumab) Biologics License Application resubmission accepted for review by U.S. FDA.Per Prescription Drug User Fee Act (PDUFA), new target action date is May 22, 2017.European Commission expected to make a final decision on marketing authorization application for Kevzara in EU in coming months.  Full Article

Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Sanofi :Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection.Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection.Monthly dosing schedule now approved in both United States and European Union.  Full Article

Regeneron says FDA approved for praluent injection
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Regeneron Pharmaceuticals Inc -:Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection.Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection.  Full Article

Sanofi receives FDA approval of Thymoglobulin for prevention of acute kidney transplant rejection
Monday, 24 Apr 2017 08:30am EDT 

April 24 (Reuters) - Sanofi SA ::Sanofi receives FDA approval of Thymoglobulin® for the prevention of acute kidney transplant rejection.Sanofi- FDA approved thymoglobulin for use in conjunction with concomitant immunosuppression in prophylaxis of acute rejection in patients receiving kidney transplant.  Full Article

EU Medicines Agency recommendations for April 2017
Friday, 21 Apr 2017 01:51pm EDT 

April 21 (Reuters) - EU Medicines Agency -:EU Medicines Agency recommendations for April 2017.EU Medicines Agency recommends approval granting of a marketing authorisation for Sandoz's Rixathon Non-Hodgkin's Lymphoma (NHL), chronic lymphocytic leukaemia.Recommends approval of Sanofi SA and Regeneron's Kevzara (Sarilumab) for treatment of rheumatoid arthritis.Recommends approval of Biogen Spinraza drug for spinal muscular atrophy drug.Recommends approval of Pfizer's Besponsa for treatment of acute lymphoblastic leukaemia.Recommends approval of Biomarin Neuronal Ceroid Lipofuscinosis drug.Recommends approval of GMP-Orphan SA's Cuprior for treatment of Wilson's disease.Recommends approval of Almirall's Skilarence for treatment of psoriasis.Recommends approval of Mylan S.A.S' Febuxostat Mylan for prevention and treatment of hyperuricaemia.  Full Article

Actis portfolio company MédiS Group announces acquisition of Winthrop Pharma Senegal from Sanofi
Wednesday, 19 Apr 2017 09:00am EDT 

April 19 (Reuters) - Actis::Actis portfolio company MédiS group announces the acquisition of Winthrop Pharma Senegal from Sanofi.Actis -portfolio company MédiS, a major pharmaceutical company based in Tunisia, has acquired Winthrop Pharma Senegal from Sanofi.  Full Article

Sanofi appoints Bill Sibold as executive vice president for Sanofi Genzyme
Wednesday, 5 Apr 2017 08:30am EDT 

Sanofi : Appoints Bill Sibold as Executive Vice President Sanofi Genzyme, effective July 1, 2017 . Sibold currently serves as head of Sanofi Genzyme's Global Multiple Sclerosis, Oncology and Immunology organization, a position he has held since January 2016 and where he has led preparation for the global launches of Dupilumab and Sarilumab .Sibold will now lead the company's efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology, company adds in statement.  Full Article

Evotec achieves first milestone in diabetes alliance with Sanofi
Wednesday, 5 Apr 2017 01:29am EDT 

Evotec AG : Says achieves first milestone in diabetes alliance with sanofi .Says triggers a payment of eur 3.0 m to evotec.  Full Article

U.S. list price for Sanofi, Regeneron's Dupixent $37,000
Tuesday, 28 Mar 2017 11:47am EDT 

Sanofi : Says U.S. list price of newly approved Dupixent atopic dermatitis drug $37,000 per patient per yearFurther company coverage: [SASY.PA] (Reporting by Ben Hirschler) ((uk.online@reuters.com;)).  Full Article

U.S. FDA says approves new eczema drug Dupixent
Tuesday, 28 Mar 2017 11:47am EDT 

U.S. FDA: FDA approves new eczema drug Dupixent . FDA granted the application for Dupixent priority review and breakthrough therapy designation .FDA granted the approval of Dupixent to Regeneron Pharmaceuticals Inc.  Full Article

More From Around the Web

UPDATE 2-Sanofi beats profit forecasts, upbeat on prospects for eczema drug

PARIS, April 28 French drugmaker Sanofi's profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.